Shook Hardy Bacon Shook Hardy Bacon Menu


Success fosters insight; insight informs success. Our representative matters look beyond the immediate solution to the next challenge facing your business and industry.

Of course, past outcomes afford no guarantee of future results. Every case is different and must be judged on its own merits.

Filter By:
Success | Pharmaceutical and Medical Device

Shook Wins Full Defense Verdict for Medical Device Maker

In a case where the plaintiff sought up to $40 million in damages, a Florida jury found for Shook's client on all counts after a four-week trial. After the win, the Shook team was nominated for "Litigators of the Week" by Litigation Daily.

Success | Pharmaceutical and Medical Device

U.S. Supreme Court Denies Cert to Mirena MDL Plaintiffs

The U.S. Supreme Court has denied a petition for writ of certiorari filed by plaintiffs in the Mirena® multidistrict litigation, effectively ending litigation in federal courts that involved more than 1,300 plaintiffs and lasted more than five years.

Success | Pharmaceutical and Medical Device

Shook Team Obtains Third Win This Year for Pharmacia

A Shook team has obtained their third win in a year for Pharmacia & Upjohn Co. LLC (Pharmacia), the maker of the corticosteroid drug Depo-Medrol® (methylprednisone acetate).

Success | Pharmaceutical and Medical Device

Shook Obtains Back-to-Back Wins for Medtronic In Product Liability Cases

Shook teams have obtained back-to-back wins for Medtronic, manufacturer of surgical and medical devices, persuading federal courts in Michigan and Texas to dismiss product liability claims against the company.
Success | Pharmaceutical and Medical Device

Eleventh Circuit Affirms Summary Judgment for Marketers of Enbrel

The Eleventh Circuit has affirmed a lower court’s grant of summary judgment in favor of the makers and marketers of the biologic drug Enbrel, finding that the plaintiffs' injury claims were barred by the learned intermediary doctrine and that the direct “patient labeling requirement” in FDA medication guidelines did not preempt application of the doctrine.